Subscribe
agreement-istock-480052842_mediaphotos
mediaphotos / iStockphoto.com
15 March 2017Americas

Mylan settles cancer drug patent dispute with Genentech

Mylan has entered a settlement with Genentech and its parent company, Roche, in relation to patents for cancer drug Herceptin (trastuzumab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Chugai abandons patent claim against Nippon Kayaku
12 April 2018   Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
EPO revokes Copaxone patent, clears path for Mylan
17 September 2020   The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.


Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025

Editor's picks

Americas
Trouble at the USPTO—Part II: Bracing for impact
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025
Europe
‘It’s business as usual’: ERS Genomics enjoys new EPO patent after CRISPR gambit pays off
27 February 2025

More on this story

Asia
Chugai abandons patent claim against Nippon Kayaku
12 April 2018   Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
EPO revokes Copaxone patent, clears path for Mylan
17 September 2020   The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.

More on this story

Asia
Chugai abandons patent claim against Nippon Kayaku
12 April 2018   Japan-based Chugai Pharmaceuticals has announced it has withdrawn its patent infringement claim against generic anti-cancer business Nippon Kayaku.
Big Pharma
EPO revokes Copaxone patent, clears path for Mylan
17 September 2020   The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.

More features

Trouble at the USPTO—Part II: Bracing for impact
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
Trump chooses crypto-focused litigation funding expert to lead USPTO
Novo Nordisk strikes again over Wegovy generic
Fed Circ removes Apple import watch ban threat
Blank Rome bolsters patent litigation with Houston partner hire
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’